Background Schizophrenia is one of the most common, burdensome, and costly psychiatric
disorders in adults worldwide. Antipsychotic drugs are its treatment of choice, but there is …

Background Several studies and meta-analyses have shown that mortality in people with
schizophrenia is higher than that in the general population but have used relative measures …

Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic
disorders but are ineffective for some patients and associated with side-effects and …

Atypical antipsychotics (AAPs) are commonly prescribed medications to treat schizophrenia,
bipolar disorders and other psychotic disorders. However, they might cause metabolic …

A recent increase in the literature regarding the evidence base for clozapine has made it
increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we …

People with severe mental illness have a considerably shorter lifespan than the general
population. This excess mortality is mainly due to physical illness. Next to mental illness …

Antipsychotic-induced weight gain is a major management problem for clinicians. It has
been shown that weight gain and obesity lead to increased cardiovascular and …

The lifespan of people with severe mental illness (SMI) is shorter compared to the general
population. This excess mortality is mainly due to physical illness. We report prevalence …

Individuals with schizophrenia have high levels of medical comorbidity and cardiovascular
risk factors. The presence of 3 or more specific factors is indicative of metabolic syndrome …

Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as
obesity, hyperglycemia, dyslipidemia and the metabolic syndrome) that are associated with …